HspE7 plus Poly-ICLC: Interim Phase I data

Data from the third cohort of patients in an open-label, U.S. Phase I trial showed that after 5 weeks, treatment with 500 µg HspE7 and 1,000 ug Poly-ICLC was well tolerated. The study is enrolling 24 ...